The drug, Rolditamig Deuderuxtecan, also known as TQB2102, is a potential HER2 bispecific antibody-drug conjugate (ADC) being evaluated for the treatment of HER2-expressing cancers.
CTTQ is a subsidiary of Sino Biopharmaceutical Ltd.
Under the agreement, Cipla will handle local clinical development, regulatory approvals and commercialisation across the seven licensed markets. CTTQ will continue to manufacture and supply the drug.
The companies didn’t disclose the financial terms of the agreement.
What is TQB2102?
TQB2102 is being studied across cancers that express HER2, a protein that can help drive the growth of certain cancer cells.
The companies said the drug has shown encouraging clinical potential in patients with HER2-low advanced breast cancer.
TQB2102 is an antibody-drug conjugate, or ADC—a type of cancer therapy designed to use an antibody to identify a particular target on cancer cells and deliver a cancer-killing drug to them more directly.
In this case, the drug is designed to target HER2. As a bispecific ADC, it is engineered to bind to two sites on the HER2 protein, potentially helping it target cancer cells more effectively.
The treatment remains under clinical evaluation, meaning its eventual availability in Cipla’s licensed markets will depend on further development and regulatory approvals.
Cipla adds to oncology pipeline
The agreement gives Cipla access to a late-stage oncology asset without requiring it to develop the molecule from scratch.
CTTQ will retain responsibility for manufacturing and supplying TQB2102, while Cipla brings its local clinical, regulatory and commercial infrastructure in India, South Africa and the other licensed markets.
Cipla Managing Director and Global CEO Achin Gupta said the agreement strengthens the company’s oncology portfolio with a promising HER2-targeted ADC and could help accelerate development and patient access, subject to regulatory approvals.
“Expanding global access to medicines developed by SBP Group is a central part of our strategy,” Sino Biopharmaceutical Group CEO Eric Tse said.
The companies said the partnership is intended to speed up local development and regulatory approvals across the licensed territories.
Cipla shares closed 0.89% lower at ₹1,410.80 on the NSE on Monday, August 31.
